These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34963120)

  • 1. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
    Klamroth R; Sinn M; Pollich C; Bischoff S; Lohneis A; Orlovic AM; Wisłocka L; Habbel P; de Wit M; Späth-Schwalbe E; Scholz CW; Riess H
    Oncol Res Treat; 2022; 45(4):178-185. PubMed ID: 34963120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
    Schaefer JK; Li M; Wu Z; Basu T; Dorsch MP; Barnes GD; Carrier M; Griggs JJ; Sood SL
    J Thromb Haemost; 2021 Jan; 19(1):212-220. PubMed ID: 33104289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
    Noble SI; Nelson A; Fitzmaurice D; Bekkers MJ; Baillie J; Sivell S; Canham J; Smith JD; Casbard A; Cohen A; Cohen D; Evans J; Fletcher K; Johnson M; Maraveyas A; Prout H; Hood K
    Health Technol Assess; 2015 Oct; 19(83):vii-xxiii, 1-93. PubMed ID: 26490434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Step down to 6 months of prophylactic-dose low molecular weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): A pilot study.
    Popov J; Coelho S; Carrier M; Sperlich C; Solymoss S; Routhier N; Shivakumar S; Aibibula W; Kahn SR; Tagalakis V
    J Thromb Haemost; 2022 Aug; 20(8):1868-1874. PubMed ID: 35587536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
    van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
    J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
    Cosmi B
    Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
    [No Abstract]   [Full Text] [Related]  

  • 8. How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis.
    Schaefer JK; Elshoury A; Nachar VR; Streiff MB; Lim MY
    J Natl Compr Canc Netw; 2021 Oct; 19(10):1203-1210. PubMed ID: 34666314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
    Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
    J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
    Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
    JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
    Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
    BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
    Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
    Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
    Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR
    Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.
    Martins MA; Silva TF; Fernandes CJ
    Curr Oncol Rep; 2023 May; 25(5):425-432. PubMed ID: 36928825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants.
    Wee B; Lai J; Khattak Z; Kwok A; Donarelli C; Ho P; Lim HY; Lui B
    J Thromb Thrombolysis; 2024 Apr; 57(4):658-667. PubMed ID: 38393675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.